William Blair & Company
AQST icon

William Blair & Company’s Aquestive Therapeutics AQST Stock Holding History

William Blair & Company’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61K Buy
14,652
+87
+0.6% +$366 ﹤0.01% 1753
2026
Q1 		$60.4K Buy
+14,565
New +$59.1K ﹤0.01% 1670

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

William Blair & Company's AQST Position: Q2 2026 in Review

William Blair & Company increased its Aquestive Therapeutics (AQST) stake by 0.6% in Q2 2026, buying an estimated $366 and bringing the position to 14,652 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

William Blair & Company first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • William Blair & Company held 14,652 shares of Aquestive Therapeutics worth $61K as of Q2 2026.
  • William Blair & Company bought 87 Aquestive Therapeutics shares in Q2 2026, an estimated $366.
  • Aquestive Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1753 holding.
  • William Blair & Company first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.